Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC

ROCKVILLE, Md. and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a…